share_log

復星醫藥：海外監管公告 - 關於續展及新增擔保額度的公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 26 08:58
Summary by Moomoo AI
上海復星醫藥（集團）股份有限公司（「復星醫藥」）於2024年3月26日宣布，將提請股東大會批准，為集團內部控股子公司及其它控股子公司續展及新增担保額度，總計不超過人民幣352億元。該担保額度將用於支持集團經營計劃，包括為控股子公司間的互相担保，以及控股子公司使用自有資產為履約義務提供担保。若被担保方為非全資控股子公司，集團將按持股比例承擔相應的担保責任。截至公告日，集團無逾期担保事項，並特別提示投資者注意相關風險。本次担保額度有效期至2024年度股東大會結束或任何股東大會通過撤銷或更改授權決議時。復星醫藥董事會表示，此舉是基於集團經營需要，並認為担保風險可控。
上海復星醫藥（集團）股份有限公司（「復星醫藥」）於2024年3月26日宣布，將提請股東大會批准，為集團內部控股子公司及其它控股子公司續展及新增担保額度，總計不超過人民幣352億元。該担保額度將用於支持集團經營計劃，包括為控股子公司間的互相担保，以及控股子公司使用自有資產為履約義務提供担保。若被担保方為非全資控股子公司，集團將按持股比例承擔相應的担保責任。截至公告日，集團無逾期担保事項，並特別提示投資者注意相關風險。本次担保額度有效期至2024年度股東大會結束或任何股東大會通過撤銷或更改授權決議時。復星醫藥董事會表示，此舉是基於集團經營需要，並認為担保風險可控。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED ON MARCH 26, 2024 THAT IT WILL APPROVE THE PETITION AT THE GENERAL MEETING TO EXTEND AND ADD A COLLATERAL AMOUNT FOR THE GROUP'S INTERNAL HOLDING SUBSIDIARIES AND OTHER HOLDING SUBSIDIARIES, TOTALING NO MORE THAN RMB 352 BILLION. The amount of coverage will be used to support the Group's operational plan, including providing collateral for mutual assurance between the holding subsidiaries and the use of equity assets by the holding subsidiary for performance obligations. If the insured party is a non-wholly-owned subsidiary, the Group will assume the corresponding liability in proportion to the shareholding. As of the date of the announcement, the Group has no outstanding insurance concerns and specifically...Show More
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED ON MARCH 26, 2024 THAT IT WILL APPROVE THE PETITION AT THE GENERAL MEETING TO EXTEND AND ADD A COLLATERAL AMOUNT FOR THE GROUP'S INTERNAL HOLDING SUBSIDIARIES AND OTHER HOLDING SUBSIDIARIES, TOTALING NO MORE THAN RMB 352 BILLION. The amount of coverage will be used to support the Group's operational plan, including providing collateral for mutual assurance between the holding subsidiaries and the use of equity assets by the holding subsidiary for performance obligations. If the insured party is a non-wholly-owned subsidiary, the Group will assume the corresponding liability in proportion to the shareholding. As of the date of the announcement, the Group has no outstanding insurance concerns and specifically urges investors to be aware of the risks involved. This guarantee amount shall be effective until the end of the 2024 General Meeting or upon the approval of any General Meeting to revoke or amend the authorization. The board of directors of Fustar Pharmaceuticals stated that the move was based on the Group's operating needs and considered that the risks of insurance were manageable.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more